Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Articles published by Verge Genomics

Verge Genomics Announces Milestones in Collaboration with Lilly to Discover and Develop Novel Treatments for ALS
From Verge Genomics
Via GlobeNewswire
Tickers LLY
Verge Genomics and Ferrer Announce Agreement to Co-Develop Clinical-Stage ALS Therapy VRG50635
From Verge Genomics
Via GlobeNewswire
Verge Genomics to Present at Evercore ISI 2024 Emerging Biotech Conference
From Verge Genomics
Via GlobeNewswire
Verge Genomics Announces Initiation of Proof-of-Concept Study for the Treatment of Amyotrophic Lateral Sclerosis (ALS) with VRG50635
From Verge Genomics
Via GlobeNewswire
Verge Genomics to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 11, 2024
From Verge Genomics
Via GlobeNewswire
Verge Genomics Will Use Modality.AI in Its ALS Phase 1b Clinical Trial of Its Lead Drug Candidate VRG50635
From Verge Genomics
Via GlobeNewswire
Verge Genomics Announces Artificial Intelligence-Enabled Drug Discovery Collaboration with Alexion for Rare Neurodegenerative and Neuromuscular Diseases
From Verge Genomics
Via GlobeNewswire
Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS
From Verge Genomics
Via Business Wire
Verge Genomics to Present at Mass General Brigham & Bank of America World Medical Innovation Forum
From Verge Genomics
Via Business Wire
Verge Genomics to Incorporate Emerald Digital Health Technology into its ALS Phase 1b Proof-of-Concept Clinical Trial
From Verge Genomics
Via Business Wire
Verge Genomics to Present at 41st Annual J.P. Morgan Healthcare Conference on January 12, 2023
From Verge Genomics
Via Business Wire
Verge Genomics Appoints Diego Cadavid, M.D., as Chief Medical Officer
From Verge Genomics
Via Business Wire
Verge Genomics to Present at Upcoming Investor Conferences in November
From Verge Genomics
Via Business Wire
Alice Zhang, CEO & Co-founder of Verge Genomics, Recognized Today by Both Fortune and Fierce Biotech as a Pioneer in AI-Driven Drug Discovery
From Verge Genomics
Via Business Wire
Verge Genomics Initiates First-In-Human Dosing in Phase 1 Trial of VRG50635, a Novel Therapeutic for Amyotrophic Lateral Sclerosis
From Verge Genomics
Via Business Wire
Verge Genomics Appoints John Applegate as Chief Financial Officer
From Verge Genomics
Via Business Wire
Verge Genomics Honored by Goldman Sachs for Entrepreneurship
From Verge Genomics
Via Business Wire
Fierce Biotech Names Verge Genomics a 2022 “Fierce 15” Biotech Company
From Verge Genomics
Via Business Wire
Alfred W. Sandrock, Jr., M.D., Ph.D., Joins Verge Genomics’ Board of Directors
From Verge Genomics
Via Business Wire
Verge Genomics to Present at 40th Annual J.P. Morgan Healthcare Conference on January 11, 2022
From Verge Genomics
Via Business Wire
Verge Genomics Secures $98 Million in New Financing
From Verge Genomics
Via Business Wire
Verge Genomics Adds Independent Director Andrew Allen, M.D., Ph.D., to its Board of Directors
From Verge Genomics
Via Business Wire
Verge Genomics Announces Three-Year Collaboration With Lilly to Discover and Develop Novel Treatments Using Its AI-Driven All-in-Human Platform
From Verge Genomics
Via Business Wire
Verge Genomics Presents Preclinical Data Supporting Broad-Spectrum Potential of Its Novel, Oral Antiviral at the 31st European Congress of Clinical Microbiology & Infectious Diseases
From Verge Genomics
Via Business Wire
Verge Genomics Announces the Addition of Mario Saltarelli, M.D., Ph.D., to its Scientific Advisory Board
From Verge Genomics
Via Business Wire
Verge Genomics Names Robert Scannevin, Ph.D., Chief Scientific Officer
From Verge Genomics
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.